Prof Seymour speaks with ecancer at the 2017 ASH annual meeting about the randomized phase 3 MURANO study, looking into the use of venetoclax plus rituximab versus bendamustine plus rituximab for patients with relapsed / refractory CLL. The primary endpoint was investigator-assessed progression free survival.
He highlighted that the primary analysis of MURANO shows a profound improvement in progression free survival vs standard bendamustine plus rituximab chemoimmunotherapy, with consistent effects in all-risk subsets.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.